Mon, Nov 04, 2024
Despite this setback, Sun Pharma’s stock has rallied 43 per cent year-to-date, fueled by growth in speciality drugs, emerging markets, and domestic sales.
More >
Mon, Oct 28, 2024
Led by growth in its domestic business, the specialty generic pharma company is expected to post good July-September quarter.
Wed, Sep 11, 2024
Share Market News: The Sensex ended 398.1 points lower at 81,523.2 while the Nifty50 settled at 24,918.5, down 122.7 points from its previous close.
Mon, Feb 07, 2022
Sun Pharma rose over 40 percent in the last 1 year compared to 17 per cent upside seen in the Nifty50 in the same period and the rally is not over yet, suggest experts.
Wed, Feb 02, 2022
According to the press statement of Sun Pharma, the board of directors has fixed Thursday, February 10, 2022, as the record date to determine the names of the equity shareholders, who shall be entitled to receive payment towards interim dividend of the Company for the current fiscal.”
Tue, Feb 01, 2022
We have collated a list of recommendations from various global brokerage firms according to a Zee Business TV report.
Mon, Jan 31, 2022
While the margins of the company contracted by 60 basis points to 26.4 per cent in the third quarter of FY22 from 27 per cent in a year ago quarter.
Mon, Jan 17, 2022
The Indian markets could consolidate on Monday tracking muted global cues but there will be a stock-specific action in which global brokerages tweaked their rating or specific reports.
Fri, Dec 31, 2021
The benchmark indices have given over 20 per cent return in one year so far. The buying interest was broadly seen from all sectors.
Wed, Dec 29, 2021
The rise of the Covid-19 variant Omicron has once again brought pharma shares in focus.
Thu, Dec 23, 2021
Organisation of Pharmaceutical Producers of India (OPPI) Director-General K G Ananthakrishnan told PTI that it is crucial for the industry to further build momentum towards the gains secured over the course of the pandemic which will help it carve a niche in the global pharma value chain.
Wed, Nov 03, 2021
Global brokerage firms such as CLSA, Jefferies, Macquarie raised their target price on Sun Pharma post September quarter results.
Tue, Nov 02, 2021
Pharma giant Sun Pharmaceutical Industries on Tuesday reported 13 per cent rise in Profit After Tax (PAT), beating expectation of the street.
Thu, Oct 28, 2021
Homegrown pharma major Sun Pharmaceutical Industries Ltd on Thursday said it has launched its medicine ILUMYA used in the treatment of adults with moderate-to-severe plaque psoriasis in Canada.
Wed, Oct 27, 2021
In the 20-share index, 17 advanced while 3 declined. The 52-week high is 14,938.25. The biggest gainers were Divi’s Laboratories Limited followed by Sun Pharmaceuticals Industries Limited and Strides Pharma Limited which were up almost 2.9, 2.1 and 2.1 per cent respectively
Fri, Sep 10, 2021
On the eve of Ganesh Chaturthi, Market Experts and Analysts have suggested 6 vignaharta shares which can give huge profits and good returns to the investors in a period of one year.
Fri, Jul 30, 2021
The pharmaceutical major — Sun Pharma on Friday reported in-line first-quarter results, as expected by the majority of the brokerages, it posted a net profit of Rs 1,444.17 crore for the June-ended quarter of the financial year 2021-22, as compared to a net loss of Rs 1,655.6 crore in the same period last year.
Fri, May 28, 2021
Amid profit booking and lower-than-expected quarter-four estimates, Sun Pharma declined around four per cent to Rs 673 per share at around 2:30 pm on the BSE intraday trade on Friday. The stock is the top laggard in the Nifty Pharma index, which is declined most than its sectoral peers.
Thu, May 27, 2021
Ahead of its fourth-quarter results, the experts predict Sun Pharma to report huge profit year-on-year basis. In this regard, Zee Business Senior Equity Research Analyst Devanshi Ashar expects the pharma major’s profit to rise over three-fold in the last quarter of fiscal 2020-2021.
Fri, Apr 02, 2021
Sharekhan says that Sun Pharma’s specialty business is on the path to improvement and is expected to gain traction. Two of its existing specialty products - Ilumya and Cequa are witnessing a rise in the prescription numbers and the sales have almost doubled over the past year, attributable to a strong growth in the US, while expansion in Europe and strengthening presence in Japan have also supported the growth
Tue, Dec 15, 2020
Among the top 30 companies Mylan clocked the highest growth of 144% for November followed by Glenmark Pharma(+11%), IPCA Labs (+10%) and Ajanta Pharma(+10%) clocking double digit growth while Novartis, Micro, Indoco Remedies, FDC & Mankind Pharma were impacted the most. With 144% growth for the month (sales of Rs 920 m), Mylan has been the standout performer for the month primarily aided by Rs 540 mn sales contribution from its COVID treatment drug, Desrem. Notably, Desrem was the second largest selling brand in IPM for Nov20. Sun Pharma, Cipla, Cadila Healthcare, Torrent Pharma, DRL, Eris Life were among some local listed players that clocked a single digit growth.
Sun Pharma Specialty business is witnessing improved traction. Pick up in the US specialty business coupled with likely traction from a sturdy new product launch pipeline, would fuel the growth of the US business. Moreover, geographic expansion/increasing penetration for specialty portfolios, in markets other than the US, would also aid the growth of specialty portfolios. Healthy growth in chronic therapies along with new launches gaining traction and a possible improvement in acute therapies is likely to fuel growth in the domestic formulations business.
Fri, Dec 11, 2020
Sun Pharmaceutical's efforts around specialty portfolio ramp up are yielding favourable progress as prescription trends around the key products suggest growth on a QoQ basis. Levulan which was significantly below pre COVID levels has broadly normalized but Nirmal Bang says needs to monitor the impact of resurgence in COVID cases. In fact, seeing faint signals of an unfavourable impact of the second COVID wave as trends seems to suggest weakening prescription volumes across product categories in the last week of November.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
